Supported by Siparex ETI, Winncare announces having signed an exclusivity agreement for the acquisition of the company Scemed

Photo credit © BCE

( — The acquisition of Scemed, one of the main French manufacturers and distributors of medical transfer and hygiene equipment, would represent the 3rd structuring external growth operation carried out by Winncare since the arrival of Siparex ETI to its capital as majority shareholder in 2021.

The Winncare Group, chaired by Laurent Faugère, is one of the European leaders in the manufacturing of medical equipment intended to improve the lives of people losing their autonomy, and those who take care of them (carers, caregivers). The Group, present in two strategic markets (home support and EHPAD), has a complete range of products (therapeutic mattresses and cushions to prevent pressure sores, connected objects and lift cushions to manage falls, medical beds, transfer systems , etc.) and services.

This broad portfolio has been strengthened in recent years, both through organic growth and acquisitions. With 5 commercial subsidiaries in France, Spain, Denmark, Poland and the United Kingdom as well as 9 production units (France, United Kingdom, Spain, Poland and Tunisia), Winncare is now positioned as the European leader in its sector. The Group has doubled in size since the entry of Siparex ETI into the capital, with a turnover of around 150 MEUR, and employs nearly 800 employees.


Source link -87